Astellas and Seagen's Padcev wins full FDA approval, notching expanded label in tough-to-crack urothelial cancer

Josh Sullivan

Two years after Seagen and Astellas won a conditional FDA approval to target urothelial cancer, the pair’s Padcev drug has been given a full endorsement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas and Seagen's Padcev wins full FDA approval, notching expanded label in tough-to-crack urothelial cancer

Josh Sullivan

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Biotech seed rounds sink to lowest level in years as industry slump drags on

US drugs rely heavily on ingredients made overseas, new report shows

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Astel­las and Seagen's Pad­cev wins full FDA ap­proval, notch­ing ex­pand­ed la­bel in tough-to-crack urothe­lial can­cer

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Astellas and Seagen's Padcev wins full FDA approval, notching expanded label in tough-to-crack urothelial cancer